Drug intelligence / Profile preview

Fortinn

Development stage: Unknown
Lead developer: INNventa Pharm
Modality: Peptides
Administration: Oral

Overview

Fortinn is a nutraceutical product developed by INNventa Pharm, formulated to support joint health and cartilage integrity. Its primary active ingredient is Fortigel, a specific composition of bioactive collagen peptides that have been shown to stimulate the metabolism of chondrocytes, leading to increased synthesis of type II collagen and proteoglycans in the extracellular matrix of articular cartilage. By promoting cartilage regeneration and reducing inflammation, Fortinn is used to manage symptoms of osteoarthritis, joint wear and tear, and sports-related joint stress. It is typically supplemented with Vitamin C to further support collagen synthesis and is administered as an oral powder.

Brand names: FortinnFortinn Strong
Other names: Fortigel

Targets

FMOD (Fibromodulin / FMOD)COL2 (Type II Collagen)

Beyond the preview

Go deeper on Fortinn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fortinn.

Explore the full profile